Thirdly, chemoresistance against EGFR tyrosine kinase inhibitors (EGFR-TKIs) such as Erlotinib was observed in patients with non-small-cell-lung cancer (NSCLC) harboring an EGFR T790 M mutation which led to reduced phosphorylation of Hsp90 and final ubiquitination and degradation of the protein [63]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.